MDSpire - Takeaway
From the Journals

Mirtazapine Cuts Meth Use in Phase 3 Trial

Reduces days of use with no differences in depression, sleep, or quality of life

Share

  • 1

    Mirtazapine reduces methamphetamine use in a phase 3 trial.

  • 2

    339 patients participated over 12 weeks.

  • 3

    Mirtazapine group saw a 7-day reduction in use days.

  • 4

    Adverse effects included drowsiness (47%) and weight gain (10%).

  • 5

    No significant changes in depression or quality of life metrics.

Original Source(s)

Mirtazapine Cuts Meth Use in Phase 3 Trial

  • by Andrea Surnit

  • April 1, 2026

Related Content

Bipolar Psychosis: Examining Diagnostic Boundaries

Investigators synthesize schizophrenia comorbidity and psychotic symptom profiles across bipolar populations.

Mental Health Content Accuracy Varies

Researchers found misinformation rates ranged from 0% to 57% across platforms and topics, with higher rates reported in several TikTok studies compared with YouTube.

GLP-1 Drugs Examined in Psychiatric Outcomes

Researchers evaluate mental health trajectories with antidiabetic therapies in patients with depression or anxiety.